News

GNI’s China-based affiliate, Shanghai Genomics, is in the process of preparing its Phase I trial for the drug, F351. Jun Wu‚ chief scientific officer of GNI, and Shanghai

The drug-drug interaction study comprised 24 healthy volunteers and was performed in Germany. Administration of intravenous iclaprim at the supra-therapeutic dose was assessed to be safe for clinical

In partnership with Sanarus, these centers will participate in regional and national efforts to increase patient and primary care physician awareness of the Visica 2 treatment as a

Tamsulosin hydrochloride capsules have proven to be bio-equivalent to Flomax capsules, which is indicated for the treatment of benign prostatic hyperplasia. The total market for both generic and

The trial is a randomized, double-blind safety and efficacy trial in which Excellarate is topically administered once or twice over the course of the study, with a goal

The drug was launched in the US as Lialda in March this year, and the UK launch is the first in a European country. Shire licensed the rights

The effects of Teverelix long acting (LA) in this benign prostatic hyperplasia (BPH) study were marked and sustained as well as being both clinically and statistically significant. Following

Under the agreement, Baxa has exclusive sales and distribution rights for all worldwide healthcare markets for the MedKeeper software. Baxa Corporation plans to launch the MedKeeper software tool

Alkermes will receive $166.3 million upon closing of the transaction and up to an additional $7.7 million subject to the terms and conditions of an escrow arrangement that